MedTrace Logo

Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia

NCT00515879 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.

Conditions

Interventions

DRUG

D-cycloserine

50 mg

BEHAVIORAL

Cognitive behavioral therapy (CBT)

CBT sessions aim to help participants become more comfortable with social situations.

DRUG

Placebo

Same dosage as active pill

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Boston University Charles River Campus

    lead OTHER

Principal Investigators

  • Stefan G. Hofmann, PhD · Boston University

  • Mark H. Pollack, MD · Massachusetts General Hospital

  • Jasper A. Smits, PhD · Southern Methodist University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515879 on ClinicalTrials.gov